Pharmena S.A. (PHR.WA)
PLN 4.38
(0.69%)
PLN 4.38
(0.69%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 34.87 Million PLN | 6818.88% |
| 2022 | -519 Thousand PLN | 87.05% |
| 2021 | -4 Million PLN | 33.57% |
| 2020 | -6.03 Million PLN | 41.09% |
| 2019 | -10.24 Million PLN | -12442.17% |
| 2018 | 83 Thousand PLN | 104.08% |
| 2017 | -2.03 Million PLN | -77.93% |
| 2016 | -1.14 Million PLN | 59.8% |
| 2015 | -2.84 Million PLN | 24.94% |
| 2014 | -3.78 Million PLN | -181.62% |
| 2013 | -1.34 Million PLN | 55.39% |
| 2012 | -3.01 Million PLN | -533.59% |
| 2011 | 694.89 Thousand PLN | 1137.44% |
| 2010 | -66.98 Thousand PLN | -112.77% |
| 2009 | 524.64 Thousand PLN | 74.51% |
| 2008 | 300.63 Thousand PLN | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -1.08 Million PLN | -200.09% |
| 2024 Q2 | -700 Thousand PLN | 10.11% |
| 2023 Q1 | 157 Thousand PLN | 133.33% |
| 2023 Q3 | 35.98 Million PLN | 1628.5% |
| 2023 Q2 | -2.35 Million PLN | -1599.36% |
| 2023 Q4 | 1.08 Million PLN | -96.98% |
| 2023 FY | 34.87 Million PLN | 6818.88% |
| 2022 Q3 | 145 Thousand PLN | 145.74% |
| 2022 Q2 | -317 Thousand PLN | -355.65% |
| 2022 Q4 | -471 Thousand PLN | -424.83% |
| 2022 FY | -519 Thousand PLN | 87.05% |
| 2022 Q1 | 124 Thousand PLN | 108.73% |
| 2021 Q2 | -1.81 Million PLN | -467.71% |
| 2021 FY | -4 Million PLN | 33.57% |
| 2021 Q4 | -1.42 Million PLN | -228.94% |
| 2021 Q3 | -432 Thousand PLN | 76.15% |
| 2021 Q1 | -319 Thousand PLN | 88.19% |
| 2020 Q1 | -979 Thousand PLN | 58.69% |
| 2020 Q2 | -1.9 Million PLN | -94.99% |
| 2020 Q4 | -2.7 Million PLN | -546.41% |
| 2020 FY | -6.03 Million PLN | 41.09% |
| 2020 Q3 | -418 Thousand PLN | 78.1% |
| 2019 Q2 | -6.34 Million PLN | -1853.54% |
| 2019 Q4 | -2.37 Million PLN | -93.31% |
| 2019 FY | -10.24 Million PLN | -12442.17% |
| 2019 Q1 | -325 Thousand PLN | 66.77% |
| 2019 Q3 | -1.22 Million PLN | 80.69% |
| 2018 Q3 | 212 Thousand PLN | 325.53% |
| 2018 Q4 | -978 Thousand PLN | -561.32% |
| 2018 FY | 83 Thousand PLN | 104.08% |
| 2018 Q2 | -94 Thousand PLN | -109.97% |
| 2018 Q1 | 943 Thousand PLN | 281.7% |
| 2017 FY | -2.03 Million PLN | -77.93% |
| 2017 Q2 | -746 Thousand PLN | -41.02% |
| 2017 Q1 | -529 Thousand PLN | -5977.78% |
| 2017 Q3 | -239 Thousand PLN | 67.96% |
| 2017 Q4 | -519 Thousand PLN | -117.15% |
| 2016 Q3 | 277 Thousand PLN | 272.05% |
| 2016 FY | -1.14 Million PLN | 59.8% |
| 2016 Q4 | 9000.00 PLN | -96.75% |
| 2016 Q2 | -161 Thousand PLN | 87.29% |
| 2016 Q1 | -1.26 Million PLN | 34.96% |
| 2015 Q1 | -568 Thousand PLN | 51.49% |
| 2015 Q3 | 137 Thousand PLN | 129.65% |
| 2015 Q4 | -1.94 Million PLN | -1521.9% |
| 2015 FY | -2.84 Million PLN | 24.94% |
| 2015 Q2 | -462 Thousand PLN | 18.66% |
| 2014 Q4 | -1.17 Million PLN | -192.75% |
| 2014 Q2 | -843 Thousand PLN | 38.51% |
| 2014 Q1 | -1.37 Million PLN | -86.53% |
| 2014 FY | -3.78 Million PLN | -181.62% |
| 2014 Q3 | -400 Thousand PLN | 52.55% |
| 2013 Q2 | -614 Thousand PLN | -329.37% |
| 2013 Q4 | -735 Thousand PLN | -596.62% |
| 2013 FY | -1.34 Million PLN | 55.39% |
| 2013 Q1 | -143 Thousand PLN | 86.59% |
| 2013 Q3 | 148 Thousand PLN | 124.1% |
| 2012 FY | -3.01 Million PLN | -533.59% |
| 2012 Q3 | -823 Thousand PLN | 0.0% |
| 2012 Q4 | -1.06 Million PLN | -29.53% |
| 2011 FY | 694.89 Thousand PLN | 1137.44% |
| 2010 FY | -66.98 Thousand PLN | -112.77% |
| 2009 FY | 524.64 Thousand PLN | 74.51% |
| 2008 FY | 300.63 Thousand PLN | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Bioceltix S.A. | -15.81 Million PLN | 320.43% |
| BIOTON S.A. | 15.29 Million PLN | -127.99% |
| Captor Therapeutics Spolka Akcyjna | -73.01 Million PLN | 147.758% |
| Mabion S.A. | 55.06 Million PLN | 36.668% |
| Molecure S.A. | -22.1 Million PLN | 257.761% |
| NanoGroup S.A. | -7.9 Million PLN | 541.299% |
| Poltreg S.A. | -16.86 Million PLN | 306.802% |
| Pure Biologics Spólka Akcyjna | -31.71 Million PLN | 209.941% |
| Ryvu Therapeutics S.A. | -100.94 Million PLN | 134.544% |
| Synthaverse S.A. | 8.64 Million PLN | -303.273% |
| Urteste S.A. | -6.44 Million PLN | 640.887% |